Symbol="IKT"
AssetType="Common Stock"
Name="Inhibikase TherapeuticsÂ Inc"
Description="Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia."
CIK="1750149"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="15582000"
EBITDA="-18121884"
PERatio="None"
PEGRatio="None"
BookValue="4.892"
DividendPerShare="0"
DividendYield="0"
EPS="-3.1"
RevenuePerShareTTM="0.033"
ProfitMargin="0"
OperatingMarginTTM="-128.25"
ReturnOnAssetsTTM="-0.342"
ReturnOnEquityTTM="-0.603"
RevenueTTM="141930"
GrossProfitTTM="-8258499"
DilutedEPSTTM="-3.1"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.402"
AnalystTargetPrice="27"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="219.63"
PriceToBookRatio="0.492"
EVToRevenue="2.748"
EVToEBITDA="0.733"
Beta="0.826"
num_52WeekHigh="7.26"
num_52WeekLow="2.64"
num_50DayMovingAverage="3.755"
num_200DayMovingAverage="4.009"
SharesOutstanding="5300000"
DividendDate="None"
ExDividendDate="None"
symbol="IKT"
open="2.87"
high="3.02"
low="2.80"
price="2.95"
volume="49068.00"
latest_trading_day="2023-07-07"
previous_close="2.79"
change="0.16"
change_percent="5.7348%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="61"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="39"
Volume_recent_avg="223084"
Change_recent_avg="0.01"
Delta_recent_avg="0.09"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="-0.8"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="39"
Aroon_momentum_negative="61"
image_negative_thumbnail_id_1="1099"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0132.jpeg"
image_negative_thumbnail_id_2="1107"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0140.jpeg"
image_neutral_thumbnail_id_1="537"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0062.jpeg"
image_neutral_thumbnail_id_2="565"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0034.jpeg"
image_positive_thumbnail_id_1="621"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0087.jpeg"
image_positive_thumbnail_id_2="634"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0074.jpeg"
image_professor_thumbnail_id_1="1196"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
image_professor_thumbnail_id_2="1183"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0017.jpeg"
